Myriad Genetics (MYGN) Current Leases (2019 - 2026)

Myriad Genetics (MYGN) has 8 years of Current Leases data on file, last reported at $7.1 million in Q1 2026.

• Current Leases for Q1 2026 came in at $7.1 million, down 34.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.1 million (down 34.86% YoY), and the FY2025 annual result was $6.9 million, down 46.09% from the prior year.
• Current Leases grew to $7.1 million in Q1 2026 per MYGN's latest filing, from $6.9 million in the prior quarter.
• Over five years, Current Leases peaked at $17.8 million in Q3 2023 and troughed at $6.9 million in Q4 2025.
• A 5-year average of $12.7 million and a median of $13.4 million in 2022 frame the typical range for Current Leases.
• The sharpest annual moves came in 2023 and 2025: Current Leases increased 27.82% in 2023, then plunged 46.09% in 2025.
• A 5-year view of Current Leases shows it stood at $14.1 million in 2022, then increased by 14.89% to $16.2 million in 2023, then retreated by 20.99% to $12.8 million in 2024, then sank by 46.09% to $6.9 million in 2025, then rose by 2.9% to $7.1 million in 2026.
• Business Quant data shows MYGN's Current Leases at $7.1 million in Q1 2026, $6.9 million in Q4 2025, and $7.9 million in Q3 2025.